Aigen Investment Management’s Denali Therapeutics DNLI Stock Holding History

Aigen Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,075	Closed	-$175K	–	682
2025 Q3	$175K	Buy	12,075 +1,413	+13%	+$20.3K	0.03%	695
2025 Q2	$149K	Buy	+10,662	New	+$150K	0.02%	689
2023 Q3	–	Sell	-19,594	Closed	-$578K	–	887
2023 Q2	$578K	Buy	+19,594	New	+$551K	0.09%	313
2023 Q1	–	Sell	-10,751	Closed	-$299K	–	668
2022 Q4	$299K	Buy	+10,751	New	+$320K	0.04%	364
2021 Q3	–	Sell	-3,243	Closed	-$254K	–	522
2021 Q2	$254K	Sell	3,243 -322	-9%	-$19.9K	0.04%	354
2021 Q1	$204K	Buy	+3,565	New	+$239K	0.03%	539
2020 Q4	–	Sell	-12,877	Closed	-$461K	–	831
2020 Q3	$461K	Buy	+12,877	New	+$388K	0.06%	420
2020 Q1	–	Sell	-2,982	Closed	-$52K	–	1326
2019 Q4	$52K	Buy	+2,982	New	+$49.6K	0.01%	801

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aigen Investment Management's DNLI Position: Q4 2025 in Review

Aigen Investment Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 12,075 shares — an estimated $175K sold.

Aigen Investment Management first reported a position in DNLI in Q4 2019 and held it in 8 quarters. The position peaked at $578K in Q2 2023. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Aigen Investment Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Aigen Investment Management sold 12,075 Denali Therapeutics shares in Q4 2025, an estimated $175K.
Aigen Investment Management first reported a position in Denali Therapeutics in Q4 2019 and held it in 8 quarters.
Aigen Investment Management's Denali Therapeutics position peaked at $578K in Q2 2023.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.